Immunoprophylaxis of respiratory syncytial virus: global experience.
about
RSV-Induced H3K4 Demethylase KDM5B Leads to Regulation of Dendritic Cell-Derived Innate Cytokines and Exacerbates Pathogenesis In VivoA predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study.European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data.Burden of respiratory syncytial virus in hospitalized infants and young children in Amman, Jordan.A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING StudyAn evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in childrenRespiratory hospitalizations and respiratory syncytial virus prophylaxis in special populationsTrends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced DiseasesProspects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection.Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registriesPalivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors?Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study 1.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation.
P2860
Q28548423-35F59D46-A851-4947-8954-57BA507C64AAQ33390780-941A4006-CC8B-40B6-8FB7-FE6632848234Q33582499-4154BE77-50DE-41C9-A61A-1283F5032AB5Q33787759-0B3093EA-F288-402C-9148-6D9E882DF596Q34884984-C680A6DA-EC3B-4C54-9945-2E9BEE0B0A27Q35157930-BB5E1C78-D4A2-463D-89CA-719FFB0E4E67Q35587298-5E964269-650F-49DA-AACA-288D97919986Q35595950-B9726C55-1741-4374-B3FA-06A8A247966DQ35892685-D2815B9E-452A-47D3-9457-768749325A7DQ35980935-C32408A3-B531-44CB-946F-89F38FAC16CAQ36246429-EEC7BA5B-73D6-4022-8ED7-EAD6C3372ABFQ36322131-320382E1-BB60-49A8-8309-690BD17FC506Q36989863-CEB17FB5-9E24-4B35-8D1D-36FF84AEE162Q40046043-F9A928EC-9505-42F3-B1C2-C2E614E238E1Q42204657-880F245C-0B62-4A7F-A7CE-FA4AA2555177Q47132154-1B82E7F0-F37E-4E36-98D8-BD2B8CC42C32Q50262223-828C223C-C114-4761-ADA8-2A26D53855D8Q51777893-E505B6EE-246B-4896-84FE-CC61D0593930
P2860
Immunoprophylaxis of respiratory syncytial virus: global experience.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Immunoprophylaxis of respiratory syncytial virus: global experience.
@ast
Immunoprophylaxis of respiratory syncytial virus: global experience.
@en
Immunoprophylaxis of respiratory syncytial virus: global experience.
@nl
type
label
Immunoprophylaxis of respiratory syncytial virus: global experience.
@ast
Immunoprophylaxis of respiratory syncytial virus: global experience.
@en
Immunoprophylaxis of respiratory syncytial virus: global experience.
@nl
prefLabel
Immunoprophylaxis of respiratory syncytial virus: global experience.
@ast
Immunoprophylaxis of respiratory syncytial virus: global experience.
@en
Immunoprophylaxis of respiratory syncytial virus: global experience.
@nl
P2860
P921
P356
P1433
P1476
Immunoprophylaxis of respiratory syncytial virus: global experience.
@en
P2093
Eric A F Simoes
P2860
P2888
P304
P356
10.1186/RR187
P478
P5008
P577
2002-01-01T00:00:00Z
P5875
P6179
1034640169